Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Verastem Oncology
< Previous
1
2
Next >
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
October 14, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
September 28, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Participate in Upcoming Investor Conferences
September 05, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
August 28, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 08, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
July 11, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
July 05, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
June 16, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 15, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Reverse Stock Split
May 31, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
May 25, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
May 16, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Participate in Upcoming Investor Conferences
May 01, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
April 26, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
March 15, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 14, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
February 02, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
January 24, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
January 24, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Appoints Rob Gagnon to Board of Directors
December 15, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 03, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Appoints Anil Kapur to Board of Directors
October 20, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
October 04, 2022
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit